X
BCRX icon

Xponance’s BioCryst Pharmaceuticals BCRX Stock Holding History

Xponance’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211K Hold
21,137
– – ﹤0.01% 1584
2026
Q1 		$201K Sell
21,137
-1,121
-5% -$8.71K ﹤0.01% 1475
2025
Q4 		$174K Buy
22,258
+94
+0.4% +$680 ﹤0.01% 1411
2025
Q3 		$168K Buy
22,164
+248
+1% +$2.06K ﹤0.01% 1384
2025
Q2 		$196K Buy
21,916
+6,349
+41% +$59.1K ﹤0.01% 1335
2025
Q1 		$117K Buy
15,567
+671
+5% +$5.41K ﹤0.01% 1327
2024
Q4 		$112K Buy
14,896
+1,242
+9% +$9.43K ﹤0.01% 1350
2024
Q3 		$104K Buy
13,654
+674
+5% +$5.12K ﹤0.01% 1317
2024
Q2 		$80.2K Buy
12,980
+1,505
+13% +$8.3K ﹤0.01% 1257
2024
Q1 		$58.3K Buy
11,475
+94
+0.8% +$529 ﹤0.01% 1269
2023
Q4 		$68.2K Buy
11,381
+182
+2% +$1.05K ﹤0.01% 1225
2023
Q3 		$79.3K Buy
11,199
+105
+0.9% +$754 ﹤0.01% 1177
2023
Q2 		$78.1K Buy
11,094
+487
+5% +$3.91K ﹤0.01% 1207
2023
Q1 		$88.5K Hold
10,607
– – ﹤0.01% 1164
2022
Q4 		$122K Buy
10,607
+163
+2% +$2.03K ﹤0.01% 1145
2022
Q3 		$132K Buy
10,444
+370
+4% +$4.76K ﹤0.01% 1106
2022
Q2 		$107K Buy
+10,074
New +$104K ﹤0.01% 1124

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Xponance's BCRX Position: Q2 2026 in Review

Xponance held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 21,137 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #1584.

Xponance first reported a position in BCRX in Q2 2022 and has held it in 17 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Xponance held 21,137 shares of BioCryst Pharmaceuticals worth $211K as of Q2 2026.
  • Xponance left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1584 holding.
  • Xponance first reported a position in BioCryst Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.